A safer vaccine for Alzheimer's disease?

Neurobiology of Aging

Volumn 23, Issue 6, 2002, Pages 1001-1008

  Sigurdsson, Einar M ^a   Wisniewski, Thomas ^a   Frangione, Blas ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Amyloid ; Central nervous system; Immunization; Therapy

Indexed keywords

VACCINE;

ALZHEIMER DISEASE; ANTIBODY PRODUCTION; ARTICLE; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; EQUILIBRIUM CONSTANT; FIBER; HUMAN; IMMUNIZATION; INFLAMMATION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; VACCINATION;

ALZHEIMER DISEASE; ALZHEIMER VACCINES; AMYLOID BETA-PROTEIN; AMYLOIDOSIS; ANIMALS; HUMANS; IMMUNOTHERAPY, ACTIVE; MICE; SAFETY;

EID: 0036862013     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-4580(02)00124-0     Document Type: Article

References (56)

1. Bacskai B.J., Kajdasz S.T., Christie R.H., Carter C., Games D., Seubert P.et al. Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat. Med. 7(3):2001;369-372.
2. Bard F., Cannon C., Barbour R., Burke R.L., Games D., Grajeda H.et al. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6(8):2000;916-919.
3. Castano E.M., Frangione B. Alzheimer's disease from the perspective of the systemic and localized forms of amyloidosis. Brain Pathol. 1(4):1991;263-271.
4. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. Peripheral anti-Abeta antibody alters CNS and plasma Abeta clearance and decreases brain Abeta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2001.
5. Du Y., Dodel R., Hampel H., Buerger K., Lin S., Eastwood B.et al. Reduced levels of amyloid beta-peptide antibody in Alzheimer disease. Neurology. 57(5):2001;801-805.
6. Findeis M.A. Approaches to discovery and characterization of inhibitors of amyloid β-peptide polymerization. Biochim. Biophys. Acta. 1502(1):2000;76-84.
7. Frenkel D., Balass M., Katchalski-Katzir E., Solomon B. High affinity binding of monoclonal antibodies to the sequential epitope EFRH of beta-amyloid peptide is essential for modulation of fibrillar aggregation. J. Neuroimmunol. 95(1/2):1999;136-142.
8. Frenkel D., Balass M., Solomon B. N-terminal EFRH sequence of Alzheimer's beta-amyloid peptide represents the epitope of its anti-aggregating antibodies. J. Neuroimmunol. 88(1/2):1998;85-90.
9. Games D., Adams D., Alessandrini R., Barbour R., Berthelette P., Blackwell C.et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature. 373(6514):1995;523-527.
10. Gaskin F., Finley J., Fang Q., Xu S., Fu S.M. Human antibodies reactive with beta-amyloid protein in Alzheimer's disease. J. Exp. Med. 177(4):1993;1181-1186.
11. George-Hyslop P.H. Piecing together Alzheimer's. Sci. Am. 283(6):2000;76-83.
12. Hrncic R., Wall J., Wolfenbarger D.A., Murphy C.L., Schell M., Weiss D.T.et al. Antibody-mediated resolution of light chain-associated amyloid deposits. Am. J. Pathol. 157(4):2000;1239-1246. [in process citation].
13. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S.et al. Correlative memory deficits Aβ elevation, and amyloid plaques in transgenic mice. Science. 274(5284):1996;99-102.
14. Hyman B.T., Smith C., Buldyrev I., Whelan C., Brown H., Tang M.X.et al. Autoantibodies to amyloid-beta and Alzheimer's disease. Ann. Neurol. 49(6):2001;808-810.
15. Irizarry M.C., Hyman B.T. Alzheimer disease therapeutics. J. Neuropathol. Exp. Neurol. 60(10):2001;923-928.
16. Jameson B.A., Wolf H. The antigenic index: a novel algorithm for predicting antigenic determinants. Comput. Appl. Biosci. 4(1):1988;181-186.
17. Janus C., Pearson J., McLaurin J., Mathews P.M., Jiang Y., Schmidt S.D.et al. Ab peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature. 408(6815):2000;979-982.
18. Jarrett J.T., Berger E.P., Lansbury P.T.J. The carboxy terminus of the β amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry. 32(18):1993;4693-4697.
19. Ji Y., Permanne B., Sigurdsson E.M., Holtzman D.M., Wisniewski T. Amyloid β40/42 clearance across the blood-brain barrier following intra-ventricular injections in wild-type, apoE knock-out and human apoE3 or E4 expressing transgenic mice. J. Alzheimer's Dis. 3(1):2001;23-30.
20. Kane M.D., Lipinski W.J., Callahan M.J., Bian F., Durham R.A., Schwarz R.D.et al. Evidence for seeding of beta-amyloid by intracerebral infusion of Alzheimer brain extracts in beta-amyloid precursor protein-transgenic mice. J. Neurosci. 20(10):2000;3606-3611.
21. Kawarabayashi T., Younkin L.H., Saido T.C., Shoji M., Ashe K.H., Younkin S.G. Age-dependent changes in brain, CSF, and plasma amyloid β protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J. Neurosci. 21(2):2001;372-381.
22. Korth C., Stierli B., Streit P., Moser M., Schaller O., Fischer R.et al. Prion (PrPSc)-specific epitope defined by a monoclonal antibody. Nature. 390(6655):1997;74-77.
23. Kuo Y.M., Crawford F., Mullan M., Kokjohn T.A., Emmerling M.R., Weller R.O.et al. Elevated A beta and apolipoprotein E in A betaPP transgenic mice and its relationship to amyloid accumulation in Alzheimer's disease. Mol. Med. 6(5):2000;430-439.
24. Mackic J.B., Weiss M.H., Miao W., Kirkman E., Ghiso J., Calero M.et al. Cerebrovascular accumulation and increased blood-brain barrier permeability to circulating Alzheimer's amyloid β peptide in aged squirrel monkey with cerebral amyloid angiopathy. J. Neurochem. 70(1):1998;210-215.
25. Maness L.M., Banks W.A., Podlisny M.B., Selkoe D.J., Kastin A.J. Passage of human amyloid β-protein 1-40 across the murine blood-brain barrier. Life Sci. 55(21):1994;1643-1650.
26. Martel C.L., Mackic J.B., McComb J.G., Ghiso J., Zlokovic B.V. Blood-brain barrier uptake of the 40 and 42 amino acid sequences of circulating Alzheimer's amyloid β in guinea pigs. Neurosci. Lett. 206(2/3):1996;57-160.
27. Monning U, Schreiter-Gasser U, Hilbich C, Bunke D, Prior R, Masters CL, Beyreuther K. Alzheimer amyloid b/A4 protein-reactive antibodies in human sera and CSF. In: Iqbal K, McLachlan DRC, Winblad B, Wisniewski HM, editors. Alzheimer's Disease: Basic Mechanism, Diagnosis and Therapeutic Strategies. New York: Wiley; 1991, p. 557-63.
28. Morgan D., Diamond D.M., Gottschall P.E., Ugen K.E., Dickey C., Hardy J.et al. Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. 408(6815):2000;982-985.
29. Nerenberg S.T., Prasad R. Radioimmunoassays for Ig classes G, A, M, D, and E in spinal fluids: normal values of different age groups. J. Lab. Clin. Med. 86(5):1975;887-898.
30. Pallitto M.M., Ghanta J., Heinzelman P., Kiessling L.L., Murphy R.M. Recognition sequence design for peptidyl modulators of β-amyloid aggregation and toxicity. Biochemistry. 38(12):1999;3570-3578.
31. Pike C.J., Burdick D., Walencewicz A.J., Glabe C.G., Cotman C.W. Neurodegeneration induced by β-amyloid peptides in vitro: the role of peptide assembly state. J. Neurosci. 13(4):1993;1676-1687.
32. Poduslo J.F., Curran G.L. Amyloid beta peptide as a vaccine for Alzheimer's disease involves receptor-mediated transport at the blood-brain barrier. Neuroreport. 12(15):2001;3197-3200.
33. Poduslo J.F., Curran G.L., Haggard J.J., Biere A.L., Selkoe D.J. Permeability and residual plasma volume of human, Dutch variant, and rat amyloid β-protein 1-40 at the blood-brain barrier. Neurobiol. Dis. 4(1):1997;27-34.
34. Poduslo J.F., Curran G.L., Sanyal B., Selkoe D.J. Receptor-mediated transport of human amyloid β-protein 1-40 and 1-42 at the blood-brain barrier. Neurobiol. Dis. 6(3):1999;190-199.
35. Poduslo J.F., Curran G.L., Wengenack T.M., Malester B., Duff K. Permeability of proteins at the blood-brain barrier in the normal adult mouse and double transgenic mouse model of Alzheimer's disease. Neurobiol. Dis. 8(4):2001;555-567.
36. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T.et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 400(6740):1999;173-177.
37. Shibata M., Yamada S., Kumar S.R., Calero M., Bading J., Frangione B.et al. Clearance of Alzheimer's amyloid-β(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J. Clin. Invest. 106(12):2000;1489-1499.
38. Sigurdsson E.M., Lee J.M., Dong X.W., Hejna M.J., Lorens S.A. Bilateral injections of amyloid-β 25-35 into the amygdala of young Fischer rats: behavioral, neurochemical, and time dependent histopathological effects. Neurobiol. Aging. 18(6):1997;591-608.
39. Sigurdsson E.M., Lorens S.A., Hejna M.J., Dong X.W., Lee J.M. Local and distant histopathological effects of unilateral amyloid-beta 25-35 injections into the amygdala of young F344 rats. Neurobiol. Aging. 17(6):1996;893-901.
40. Sigurdsson E.M., Permanne B., Soto C., Wisniewski T., Frangione B. In vivo reversal of amyloid-β lesions in rat brain. J. Neuropathol. Exp. Neurol. 59(1):2000;11-17.
41. Sigurdsson E.M., Scholtzova H., Mehta P.D., Frangione B., Wisniewski T. Immunization with a non-toxic/non-fibrillar amyloid-β homologous peptide reduces Alzheimer's disease associated pathology in transgenic mice. Am. J. Pathol. 159(2):2001;439-447.
42. Singh V.K. Neuroautoimmunity: pathogenic implications for Alzheimer's disease. Gerontology. 43(1/2):1997;79-94.
43. Solomon B., Koppel R., Frankel D., Hanan-Aharon E. Disaggregation of Alzheimer β-amyloid by site-directed mAb. Proc. Natl. Acad. Sci. U.S.A. 94(8):1997;4109-4112.
44. Solomon B., Koppel R., Hanan E., Katzav T. Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer β-amyloid peptide. Proc. Natl. Acad. Sci. U.S.A. 93(1):1996;452-455.
45. Soto C., Kindy M.S., Baumann M., Frangione B. Inhibition of Alzheimer's amyloidosis by peptides that prevent beta-sheet conformation. Biochem. Biophys. Res. Commun. 226(3):1996;672-680.
46. Soto C., Sigurdsson E.M., Morelli L., Kumar R.A., Castano E.M., Frangione B. β-Sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy. Nat. Med. 4(7):1998;822-826.
47. Vermes L.M. Cerebrospinal fluid proteins: III. Normal values of immunoglobulins G, A and M (variations related to race, sex and age). Arq. Neuropsiquiatr. 41(1):1983;25-49.
48. Walsh D.M., Hartley D.M., Kusumoto Y., Fezoui Y., Condron M.M., Lomakin A.et al. Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. J. Biol. Chem. 274(36):1999;25945-25952.
49. Webster S.D., Tenner A.J., Poulos T.L., Cribbs D.H. The mouse C1q A-chain sequence alters beta-amyloid-induced complement activation. Neurobiol. Aging. 20(3):1999;297-304.
50. Weiner H.L., Lemere C.A., Maron R., Spooner E.T., Grenfell T.J., Mori C.et al. Nasal administration of amyloid-β peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Ann. Neurol. 48(4):2000;567-579.
51. Werdelin O. Fact and speculation on the function of immune response genes in antigen presentation. Scand. J. Immunol. 14(6):1981;623-629.
52. Wisniewski T., Ghiso J., Frangione B. Biology of A beta amyloid in Alzheimer's disease (published erratum appears in Neurobiol Dis 1998 July; 5(1):65). Neurobiol. Dis. 4(5):1997;313-328.
53. Xu S., Gaskin F. Increased incidence of anti-beta-amyloid autoantibodies secreted by Epstein-Barr virus transformed B cell lines from patients with Alzheimer's disease. Mech. Ageing Dev. 94(1/3):1997;213-222.
54. Yankner B.A., Dawes L.R., Fisher S., Villa-Komaroff L., Oster-Granite M.L., Neve R.L. Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease. Science. 245(4916):1989;417-420.
55. Zlokovic B. Can blood-brain barrier play a role in the development of cerebral amyloidosis and Alzheimer's disease pathology. Neurobiol. Dis. 4(1):1997;23-26.
56. Zlokovic B.V., Ghiso J., Mackic J.B., McComb J.G., Weiss M.H., Frangione B. Blood-brain barrier transport of circulating Alzheimer's amyloid β Biochem. Biophys. Res. Commun. 197(3):1993;1034-1040.